Skip to main content
European Commission logo print header

Neuroprotection and natural history in parkinson plus syndromes: a clinical trial of the efficacy and safety of riluzole in parkinson plus syndromes

Cel

The Parkinson-Plus syndromes, Multiple System Atrophy and Progressive Supranuclear Palsy (MSA & PSP) are rapidly progressive neurodegenerative diseases, leading to severe disability and death. They are orphan diseases with neither symptomatic nor curative therapy. We will
(i) establish whether the antiexcitotoxic drugriluzole can slow the disease progression,
(ii) provide for the first time prospective data on their natural history. In U. K., France, and Germany, 800patients, stratified on MSA or PSP, will randomly be assigned to placebo orriluzole and followed double blind for 36 months. The primary efficacy criterionis survival.
The project will validate diagnostic staging, new assessment instruments and disease severity staging;
assess cognitive function, quality of life and health economics;
and establish DNA and tissue banks for basic research.
The project will comply with the GMP, GCP, GLP and GSP specifications.

Zaproszenie do składania wniosków

Data not available

System finansowania

CSC - Cost-sharing contracts

Koordynator

KING'S COLLEGE LONDON
Wkład UE
Brak danych
Adres
De Crespigny Park, Denmark Hill
SE5 8AF LONDON
Zjednoczone Królestwo

Zobacz na mapie

Linki
Koszt całkowity
Brak danych

Uczestnicy (5)